Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMI 137

Next Previous
Drug Profile

EMI 137

Alternative Names: EMI-137; GE 137

Latest Information Update: 18 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Developer Edinburgh Molecular Imaging; GE Healthcare; Kings College London; Netherlands Cancer Institute; University Medical Center Groningen
  • Class Diagnostic agents; Imaging agents; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Penile cancer; Tongue cancer
  • Phase I/II Breast cancer; Orofacial cancer
  • Phase I Thyroid cancer
  • No development reported Barrett's oesophagus; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 12 Dec 2023 EMI 137 is still in phase I development in Thyroid-cancer (Diagnosis) in Netherlands (IV)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Head-and-neck-cancer in United Kingdom (Parenteral)
  • 28 Oct 2022 No recent reports of development identified for phase-I development in Lung-cancer(Diagnosis) in United Kingdom (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top